Hims & Hers Health climbs 5.68% after FDA advisory panel backs adding BPC-157 peptide to 503A compounding list
AI Market Summary
Hims & Hers outperformed a broad risk-off tape after an FDA advisory panel voted to include the BPC-157 peptide on the 503A bulk compounding list, improving regulatory visibility for expanding peptide-based prescriptions. The move partially offsets earlier concerns flagged in FDA briefing materials. A decline in short interest may reduce incremental selling pressure and amplify sensitivity to positive catalysts ahead of the Aug. 10 earnings report.
Impact level
● Medium
Affected assets
NCSKHIMS2USD/USDT-13.49%
AI Insight · NCSKHIMS2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
The U.S. FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted during its July 23–24 meeting to add the BPC-157 peptide to the 503A bulk compounding list, allowing state-licensed pharmacies to compound the ingredient. The decision creates a regulatory pathway for Hims & Hers Health to expand its peptide prescription product lineup. The stock rose 5.68% on the day, even as the Nasdaq fell 1.96% and the S&P 500 slipped 1.32%.
